These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20036965)

  • 1. Acetyl-CoA carboxylase-a as a novel target for cancer therapy.
    Wang C; Rajput S; Watabe K; Liao DF; Cao D
    Front Biosci (Schol Ed); 2010 Jan; 2(2):515-26. PubMed ID: 20036965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetyl-CoA Carboxylases and Diseases.
    Wang Y; Yu W; Li S; Guo D; He J; Wang Y
    Front Oncol; 2022; 12():836058. PubMed ID: 35359351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation.
    Jump DB; Torres-Gonzalez M; Olson LK
    Biochem Pharmacol; 2011 Mar; 81(5):649-60. PubMed ID: 21184748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells.
    Brusselmans K; De Schrijver E; Verhoeven G; Swinnen JV
    Cancer Res; 2005 Aug; 65(15):6719-25. PubMed ID: 16061653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical genetics of acetyl-CoA carboxylases.
    Zu X; Zhong J; Luo D; Tan J; Zhang Q; Wu Y; Liu J; Cao R; Wen G; Cao D
    Molecules; 2013 Jan; 18(2):1704-19. PubMed ID: 23358327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic regulation of invadopodia and invasion by acetyl-CoA carboxylase 1 and de novo lipogenesis.
    Scott KE; Wheeler FB; Davis AL; Thomas MJ; Ntambi JM; Seals DF; Kridel SJ
    PLoS One; 2012; 7(1):e29761. PubMed ID: 22238651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential.
    Luo DX; Tong DJ; Rajput S; Wang C; Liao DF; Cao D; Maser E
    Recent Pat Anticancer Drug Discov; 2012 May; 7(2):168-84. PubMed ID: 22339356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
    Harada N; Oda Z; Hara Y; Fujinami K; Okawa M; Ohbuchi K; Yonemoto M; Ikeda Y; Ohwaki K; Aragane K; Tamai Y; Kusunoki J
    Mol Cell Biol; 2007 Mar; 27(5):1881-8. PubMed ID: 17210641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
    Harwood HJ; Petras SF; Shelly LD; Zaccaro LM; Perry DA; Makowski MR; Hargrove DM; Martin KA; Tracey WR; Chapman JG; Magee WP; Dalvie DK; Soliman VF; Martin WH; Mularski CJ; Eisenbeis SA
    J Biol Chem; 2003 Sep; 278(39):37099-111. PubMed ID: 12842871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulation of acetyl-CoA carboxylase--a potential target for the action of hypolipidemic agents.
    Munday MR; Hemingway CJ
    Adv Enzyme Regul; 1999; 39():205-34. PubMed ID: 10470374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells.
    Jones JE; Esler WP; Patel R; Lanba A; Vera NB; Pfefferkorn JA; Vernochet C
    PLoS One; 2017; 12(1):e0169566. PubMed ID: 28081256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACC2 is expressed at high levels in human white adipose and has an isoform with a novel N-terminus [corrected].
    Castle JC; Hara Y; Raymond CK; Garrett-Engele P; Ohwaki K; Kan Z; Kusunoki J; Johnson JM
    PLoS One; 2009; 4(2):e4369. PubMed ID: 19190759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal.
    Abu-Elheiga L; Matzuk MM; Kordari P; Oh W; Shaikenov T; Gu Z; Wakil SJ
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12011-6. PubMed ID: 16103361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors.
    Chen L; Duan Y; Wei H; Ning H; Bi C; Zhao Y; Qin Y; Li Y
    Expert Opin Investig Drugs; 2019 Oct; 28(10):917-930. PubMed ID: 31430206
    [No Abstract]   [Full Text] [Related]  

  • 17. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
    Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
    Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal muscle ACC2 S212 phosphorylation is not required for the control of fatty acid oxidation during exercise.
    O'Neill HM; Lally JS; Galic S; Pulinilkunnil T; Ford RJ; Dyck JR; van Denderen BJ; Kemp BE; Steinberg GR
    Physiol Rep; 2015 Jul; 3(7):. PubMed ID: 26156967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability.
    Deja S; Fletcher JA; Kim CW; Kucejova B; Fu X; Mizerska M; Villegas M; Pudelko-Malik N; Browder N; Inigo-Vollmer M; Menezes CJ; Mishra P; Berglund ED; Browning JD; Thyfault JP; Young JD; Horton JD; Burgess SC
    Cell Metab; 2024 May; 36(5):1088-1104.e12. PubMed ID: 38447582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.